Press Releases

Archives: Search / 2018

20172016201520142013201220112010200920082007

Jul 18, 2018
Thirteen presentations to be given including late breaking Phase 2 study results of BAN2401 and elenbecestat

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 13 posters and presentations from its robust Alzheimer's disease pipeline, including the Phase 2 clinical...

More
Jul 17, 2018
- BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients

Eisai Inc. announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial. This 12,000 patient study of BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily was conducted at...

More
Jul 9, 2018

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be...

More
Jul 5, 2018
- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...

More
Jul 2, 2018
Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake disorder

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced that they will present data on their investigational...

More
Jun 12, 2018
- Will accelerate discovery of next-generation immunodementia therapeutics that go beyond A-beta and tau by targeting immune mechanisms identified by human genetics

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will launch the Eisai Center for Genetics Guided Dementia Discovery, which will harness the power of human...

More
Jun 11, 2018

Eisai Inc. announced today the appointment of Lihua Yu, Ph.D., to President & Chief Data Sciences Officer, H3 Biomedicine, the cancer genomics based drug discovery company of Eisai. In her new...

More
Jun 5, 2018
Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...

More
Jun 5, 2018
RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...

More
Jun 3, 2018
-- First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN)

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA® (lenvatinib), an orally...

More
May 30, 2018
- Designation underscores the need to expand potential treatment options to help certain young patients achieve goal of seizure freedom

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for its antiepileptic drug FYCOMPA®...

More
May 24, 2018

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the...

More
May 22, 2018

Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to...

More
May 17, 2018
- Data highlights continued investigation of LENVIMA as monotherapy and in combination with Merck's KEYTRUDA across multiple cancer types under global collaboration to co-develop and co-commercialize LENVIMA

Eisai Inc. today announced the presentation of new data and analyses at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5 in Chicago. The data to be presented...

More
Apr 19, 2018
Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data

Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include...

More
Mar 30, 2018
- First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages

Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA®...

More
Mar 7, 2018

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant,...

More
Feb 15, 2018

Eisai Inc. announced today that the positive results of a Phase 3 study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (marketed as...

More
Feb 5, 2018

Eisai Inc. today announced the publication of results from a subgroup analysis of the pivotal Phase 3 study comparing eribulin mesylate (marketed as Halaven® Injection) with dacarbazine in...

More
Jan 30, 2018

Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer's disease-associated genetic variants on the behavior of brain cells,...

More
 

print email rss